Overview
INAB market data
Price History
INAB price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$4.44 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.37 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.90 – $2.73 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $9.6M · P/B 0.39.
Company News
IN8bio Q2 EPS $(0.25) Beats $(0.37) EstimateBenzinga · Aug 6, 2026, 9:58 PM
12 Health Care Stocks Moving In Thursday's After-Market SessionBenzinga · Jul 23, 2026, 9:10 PM
IN8bio Announces Publication in The Journal of Clinical Oncology Demonstrating DeltEx™ DRI Doubles Progression-Free Survival in Newly Diagnosed GlioblastomaGlobenewswire Inc · Jul 9, 2026, 12:15 PM
IN8bio Announces Publication Of Peer-Reviewed Clinical Data From Phase 1 Trial Of INB-200 In The Journal Of Clinical OncologyBenzinga · Jul 9, 2026, 12:10 PM
IN8bio Announced Updated Clinical Data Showing Improved Survival Data For Phase 1 INB-200 And Phase 2 INB-400 Studies At ASCO Annual Meeting May 29 - June 2Benzinga · Jun 1, 2026, 12:33 PM
8-K filing — IN8BIO, INC. (INAB)SEC EDGAR · Jun 1, 2026, 10:56 AM